ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Jul 22, 2021 20:26 JST
Source:
Sino Biopharmaceutical Limited
Sino Biopharmaceutical Donates Cash and Supplies Valued at RMB10 Million to Support Henan for Flood Relief and Preventing Epidemic
HONG KONG, Jul 22, 2021 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced the donation of cash and supplies valued at RMB10 million to support Henan for flood relief and preventing epidemic.
Henan province has been afflicted by the torrential rain storm and the severe flooding has drawn widespread concern. When a place is in trouble, help from all sides come to the rescue. With this thought in mind, Sino Biopharmaceutical, in fulfilling its social responsibility and living up to its role as a pharmaceutical company dedicated to healthcare, has donated both cash and emergency relief supplies each valued at RMB5 million via the Liaison Office of the Central People's Government in the Hong Kong S.A.R. These funds and supplies are to be used in supporting Henan province's efforts to provide emergency medical and rescue and relief services and prevent the emergence of an outbreak of disease or an epidemic in the wake of the devastation so as to protect the lives, safety and health of the public in Henan.
Ms. Cheng Cheung Ling, Vice Chairwoman and Executive Director of Sino Biopharmaceutical, said, "Capitalising on its professional strengths in the biopharmaceutical industry, the Group will closely monitor health issues and epidemic prevention preparations subsequent to this natural disaster, and donate supplies and medicines. Sino Biopharmaceutical regards safeguarding public health as its mission and responsibility. Let's stay together through thick and thin. Keep fighting and don't give up, Henan!"
About Sino Biopharmaceutical Limited (HKEX:1177)
Sino Biopharmaceutical Limited is a leading, innovative R&D driven pharmaceutical conglomerate in the PRC. Its business encompasses a fully-integrated chain which covers an array of R&D platforms, a line-up of intelligent production and a strong sales system. The Group's products have gained a competitive foothold in various therapeutic categories with promising potentials, comprising a variety of biopharmaceutical and chemical medicines for tumors, liver diseases, cardio-cerebral diseases, orthopedic diseases, respiratory system diseases and parenteral nutrition.
Sino Biopharm is a constituent stock of the following indices: MSCI Global Standard Indices - MSCI China Index, Hang Seng Index, Hang Seng China Enterprises Index, Hang Seng Composite Index, Hang Seng Healthcare Index, Hang Seng SCHK Mainland China Healthcare Index, Hang Seng Composite LargeCap Index, Hang Seng Composite LargeCap & MidCap Index, Hang Seng China (Hong Kong-listed) 100 Index and Hang Seng Stock Connect Hong Kong Index, etc.. Sino Biopharm was ranked as one of "Asia's Fab 50 Companies" by Forbes Asia for three consecutive years in 2016, 2017 and 2018.
For more information:
Strategic Financial Relations Limited
Vicky Lee +852 2864 4834
vicky.lee@sprg.com.hk
Fanny Yuen +852 2864 4853
fanny.yuen@sprg.com.hk
Mandy Wong +852 2114 4900
mandy.wong@sprg.com.hk
Website: www.sprg.com.hk
Source: Sino Biopharmaceutical Limited
Sectors: BioTech
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
DENSO Acquires Axia Vegetable Seeds to Realize Sustainable Agriculture
Jul 04, 2025 16:20 JST
MHIET Launches 450kW Gas Cogeneration System Capable of Hydrogen Co-Firing
Jul 04, 2025 15:13 JST
Yachiyo Engineering and NEC launch adaptation finance study in Indonesia to calculate the adaptation value of disaster prevention measures
Jul 04, 2025 13:25 JST
Fujitsu to implement store monitoring solution for METRO Inc. in Canada, enhancing operational efficiency and policy compliance
Jul 04, 2025 13:19 JST
Fujitsu to develop ETF trading platform based on TSE's CONNEQTOR and provide it to Australian Securities Exchange
Jul 03, 2025 11:14 JST
Mitsubishi Motors Launches the All-New Grandis for the European Market
Jul 02, 2025 12:10 JST
Valuufy partners with Mainichi Future Creation Lab, Supporting New Approaches to Business Sustainability
Jul 02, 2025 12:00 JST
Fujitsu launches solution to enhance customers' global supply chain resilience
Jul 02, 2025 11:32 JST
MHI Receives Order to Supply Four Circulating Water Pumps for Units 5 and 6 of Sanmen Nuclear Power Plant in China Under Collaboration with Dongfang Electric Machinery
Jul 02, 2025 11:30 JST
Multi-purpose Arena in Odaiba Aomi Area TOYOTA ARENA TOKYO Construction Completed
Jul 01, 2025 22:56 JST
1Finity, a Fujitsu company, commences operations and reveals brand identity
Jul 01, 2025 22:53 JST
MHI Thermal Systems Begins Field Test of Jointly Developed "Surplus Renewable Energy Absorption and Release System"
Jul 01, 2025 22:40 JST
Japan's Telecommunications Carriers Strengthen Disaster Response Through Collaborative Information Sharing
Jul 01, 2025 22:30 JST
JCB and Mandai Wildlife Group Deepen Partnership with exclusive discounts for JCB cardmembers
Jul 01, 2025 16:00 JST
Fujitsu provides Japan's first AI-powered cloud-based library search service
Jul 01, 2025 11:30 JST
JCB Brings Apple Pay to Cardmembers in Vietnam
Jul 01, 2025 11:15 JST
First Shipment of LNG from the LNG Canada Project
Jul 01, 2025 11:00 JST
Approval in Principle (AiP) for World's First LCO2 / Methanol Carrier
Jun 30, 2025 20:30 JST
Acropolis Rally Greece: Day 4 Sunday success and second overall for TOYOTA GAZOO Racing's Ogier
Jun 30, 2025 20:15 JST
Mitsubishi Fuso-Hino Merger: 4 Firms Collaborate for the Future of Commercial Vehicles
Jun 30, 2025 20:10 JST
More Latest Release >>
Related Release
Sino Biopharm (1177.HK) Announces 2024 Annual Results
March 20 2025 23:58 JST
Sino Biopharmaceutical (1177.HK) Announces 2024 Interim Results
August 14 2024 00:30 JST
Sino Biopharm (1177.HK) Announces 2023 Annual Results
March 29 2024 11:45 JST
Sino Biopharmaceutical (1177.HK) Announces 2023 Interim Results
August 25 2023 19:12 JST
Sino Biopharm (1177.HK) Announces 2022 Annual Results
March 31 2023 21:11 JST
Sino Biopharmaceutical (1177.HK) Announces 2022 lnterim Results, Revenue up by 5.9% to RMB15.19 billion
August 23 2022 19:51 JST
Sino Biopharmaceutical 2021 First Quarterly Profit attributable to Owners of the Parent Soars 118.5% to RMB1.91 Billion
May 24 2021 17:12 JST
Sino Biopharmaceutical 2020 Net Profit Grows to RMB2.77 Billion amid Adversity
March 23 2021 17:09 JST
Sino Biopharm Invests in Sinovac LS, A Leading COVID-19 Vaccine Company in China
December 07 2020 08:55 JST
Sino Biopharmaceutical Announces 2020 Third Quarterly Results
November 30 2020 17:20 JST
More Press release >>